Classes
DEA Class; Rx
Common Brand Names; Xanax, Niravam, Xanax XR
- Antianxiety Agents;
- Anxiolytics, Benzodiazepine
Description
Oral intermediate-acting benzodiazepine with minimally active metabolites
Approved for panic disorder, generalized anxiety disorder, and short-term treatment of anxiety symptoms in adults; rarely used in pediatric patients off-label
Avoid coadministration with opioids if possible due to potential for profound sedation, respiratory depression, coma, and death
Indications
Indicated for the short-term treatment of transient symptoms of anxiety.
Contraindications
Documented hypersensitivity
Acute narrow angle glaucoma
Concomitant use with CYP3A4 inhibitors (itraconazole, ketoconazole)
Adverse Effects
>10% (4 mg dose)
- Drowsiness (41%)
- Depression (10-15%)
- Headache (10-15%)
- Constipation (10-15%)
- Diarrhea (10-15%)
- Dry mouth (10-15%)
>10% (10 mg dose)
- Drowsiness (77%)
- Impaired coordination (40-50%)
- Increased appetite (30-35%)
- Fatigue (30-35%)
- Memory impairment (30-35%)
- Irritability (30-35%)
- Decreased salivation (30-35%)
- Cognitive disorders (20-30%)
- Insomnia (20-30%)
- Dcreased appetite (20-30%)
- Headache (20-30%)
- Lightheadedness (20-30%)
- Dysarthria (20-30%)
- Diarrhea, constipation, and nausea/vomiting (20-30%)
- Weight change (20-30%)
- Nasal congestion (15-20%)
- Decreased or increased libido (10-15%)
- Menstrual disorder (10-15%)
- Difficult micturition (10-15%)
1-10% (4 mg dose)
- Tachycardia (5-10%)
- Confusion (5-10%)
- Insomnia (5-10%)
- Nausea/vomiting (5-10%)
- Blurred vision (5-10%)
- Nasal congestion (5-10%)
- Hypotension (1-5%)
- Syncope (1-5%)
- Akathisia (1-5%)
- Dizziness (1-5%)
- Increased salivation (1-5%)
- Nervousness (1-5%)
- Tremor (1-5%)
- Weight change (1-5%)
1-10% (10 mg dose)
- Increased salivation (5-10%)
- Talkativeness (1-5%)
- Incontinence (1-5%)
Warnings
Anterograde amnesia reported with benzodiazepine use
Use caution in elderly patients
Use caution in debilitated patients
Use caution in severe respiratory depression; if signs and symptoms of respiratory depression, hypoventilation, or apnea occur, discontinue
Use caution in patients who recently received other respiratory depressants
Use caution in patients who are at risk of falls
May have prolonged effects in obese patients when discontinued; use caution
Not for us in acute alcohol intoxication
Use with caution in patients with hepatic or renal impairment
Myasthenia gravis (allowable in limited circumstances)
Use caution in cases of respiratory disease (COPD), sleep apnea, renal/hepatic disease, open-angle glaucoma (questionable), depression, suicide ideation, drug abuse
CNS depressant; may impair ability to perform hazardous tasks
Paradoxical reactions, including hyperactive or aggressive behavior reported
Cigarette smoking may decrease alprazolam concentration up to 50%
Mania and hypomania episodes reported in depressed patients
Pregnancy and Lactation
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to drug during pregnancy
Limited data from published literature reports the presence of the drug in human breast milk; there are reports of sedation and withdrawal symptoms in breastfed neonates and infants exposed to alprazolam; effects of alprazolam on lactation are unknown
Maximum Dosage
10 mg/day PO.
10 mg/day PO.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Not indicated.
How supplied
Alprazolam
tablet: Schedule IV
0.25mg
0.5mg
1mg
2mg
tablet, extended-release: Schedule IV
0.5mg
1mg
2mg
3mg
tablet, orally disintegrating: Schedule IV
0.25mg
0.5mg
1mg
2mg
oral solution: Schedule IV
1mg/mL